Eko.Ai Pte Ltd. D/B/A Us2.Ai

Singapore, Singapore  All Singapore companies → — Founded 2017
Imaging AI Specialist Specialty-Focused AI
Cardiology Radiology
Cardiology AI Radiology & Imaging AI
Series A
Claim this company

Products

Us2.ca
Us2.ai
Cardiology AI
Us2.ai is an FDA-cleared and CE-marked AI platform that fully automates echocardiography analysis, delivering comprehensive, structured cardiac reports in seconds to enhance diagnostic accuracy and workflow efficiency.

See all 1 product →

About Eko.Ai Pte Ltd. D/B/A Us2.Ai

Us2.ai (formerly Eko.Ai Pte Ltd.) is a Singapore-based healthcare AI company dedicated to combating cardiovascular disease through pioneering artificial intelligence. The company’s mission is to improve patient outcomes and expand healthcare access by democratizing echocardiograms, the most widely used tool for heart risk detection. Us2.ai’s AI-powered software provides fully automated analyses of all heart chambers using both 2D and Doppler views, generating editable reports on heart structure and function.

Their flagship product, Us2.v1 (also referred to as Echo Copilot), is FDA-cleared and CE-marked, and aims to reduce the time to process and interpret echocardiograms with zero variability and accuracy comparable to expert clinicians. The software automatically processes full echocardiographic studies from any vendor in less than two minutes, delivering complete echo reports with measurements, editable annotations, and conclusions for every heart chamber. This technology minimizes manual interventions, making echocardiogram analysis more accessible, consistent, and cost-effective. Us2.ai’s solutions are designed to integrate with existing echo devices and PACS, offering features like automated disease detection for conditions such as heart failure, cardiac amyloidosis, aortic stenosis, and pulmonary hypertension.

Focus Areas

AI-powered echocardiography analysis cardiovascular disease detection automated cardiac measurements deep learning solutions for ultrasound imaging cardiac amyloidosis heart failure aortic stenosis pulmonary hypertension strain analysis stress echocardiography

Business Intelligence

TechnologyAI-powered deep learning platform for ultrasound medical imaging biomarkers, cloud-native, integrates with existing echo devices (Us2.connect), provides fully automated analysis and structured echo reports from DICOM images

What Physicians Need to Know

Echocardiography Analysis & Reporting
Us2.ai offers an FDA-cleared AI platform that fully automates echocardiogram analysis, generating measurements, disease detection, and structured reports in seconds from a single DICOM upload. The software automates over 45, and including derived measurements, almost 60 measurements for evaluating diastolic and systolic function, covering the minimum echocardiographic dataset for a standard adult echocardiogram. This eliminates the need for manual frame selection and annotation, significantly reducing analysis time from 35-40 minutes to about 10 minutes, or even under two minutes for a draft report.
AI-Powered Cardiac Diagnostics
The platform provides AI detection across various disease areas, including heart failure (HFrEF, HFmrEF, and HFpEF), cardiac amyloidosis, aortic stenosis, and pulmonary hypertension. For cardiac amyloidosis, Us2.ai is the first platform to combine deep learning pattern recognition with guideline-based echocardiographic measurements for automated detection. It also offers the first published AI system for end-to-end automated aortic stenosis assessment, requiring zero human input.
Key Differentiators
Us2.ai stands out due to its breadth of indication, screening for multiple conditions in a single pass; depth of evidence, with results published in peer-reviewed journals; and its vendor-neutral approach, compatible with ultrasound machines from GE, Philips, Siemens, Canon, and others. It provides 100% AI automation, eliminating manual frame selection and annotation, and integrates seamlessly into existing PACS, CVIS, and reporting systems.
Technology Stack
Us2.ai utilizes deep learning and AI algorithms to process DICOM images. The system can be deployed as a cloud instance or on-premise server. It is DICOM-native and vendor-neutral, allowing integration with various ultrasound devices, AI marketplaces, and PACS/cardiology reporting systems. The software can deliver structured reports as DICOM-SR, HL7, or PDF. Minimum on-premise hardware requirements include 64 GB memory, a 16-core CPU, a GPU with 12 GB VRAM, and 1 TB SSD storage.
Regulatory & Compliance
Us2.ai is FDA-cleared (510(k) in 2021 for Us2.v1 and expanded clearance for Us2.v2 in April 2024) and CE Mark Class IIb cleared. It is also compliant with GDPR and HIPAA, ISO 27001:2022 certified, SOC 2 Type II attested, and MDSAP certified, covering regulatory expectations in the United States, Canada, Japan, Brazil, and Australia.
Physician Tip

For physicians, Us2.ai offers significantly faster and more consistent echocardiogram reports, reducing manual workload and potential for human error. The automated detection of conditions like heart failure, cardiac amyloidosis, aortic stenosis, and pulmonary hypertension can aid in earlier diagnosis and improved patient outcomes. The vendor-neutrality and seamless integration into existing workflows mean minimal disruption to current practices. The fully explainable AI outcomes allow for direct editing of annotations from the report, maintaining physician control and oversight. This tool is particularly beneficial for echo labs with long reading backlogs and those aiming for guideline-based measurements done consistently across all studies.

Us2.ai is designed for seamless integration into existing clinical workflows. It is vendor-neutral and DICOM-native, allowing it to plug into various ultrasound systems, AI marketplaces, PACS, CVIS, and reporting systems. This means results can appear natively within platforms like Merge, eliminating the need for separate logins or extra clicks. Deployment options include cloud instances or on-premise servers, and it supports DICOM-SR, HL7, or PDF for report delivery.

Products by Eko.Ai Pte Ltd. D/B/A Us2.Ai

1 product in the directory

Us2.ca
Us2.ai
Cardiology AI
Us2.ai is an FDA-cleared and CE-marked AI platform that fully automates echocardiography analysis, delivering comprehensive, structured cardiac reports in seconds to enhance diagnostic accuracy and workflow efficiency.

What the Web Says

Us2.ai (formerly Eko.Ai Pte Ltd.) is a Singapore-based company that develops FDA-cleared AI software for analyzing echocardiograms. The software automates measurements and generates draft reports in under two minutes, aiming to improve efficiency and consistency in echo labs. The company has received positive feedback from cardiologists and sonographers regarding improved measurement accuracy and workflow efficiency.

Overall: Positive

Strengths

  • Faster, more consistent echo reports and measurements.
  • Reduces analysis time from up to an hour to minutes.
  • Minimizes inter-operator variability and enhances diagnostic precision.
  • Integrates with existing ultrasound machines and PACS.
  • FDA-cleared for automated analysis and structured echo reports.
  • Helps address worldwide shortage of sonographers and long waitlist times for echoes.

Limitations

  • Not suitable for sites that read only a handful of echoes a week.
  • Not for buyers who want AI for CT, MRI, or X-ray in the same purchase.
  • Lack of a published price list.
  • Limited public reviews on platforms like G2, Glassdoor, and Capterra.
  • Some users may prefer alternatives like Ultromics for specific needs like finding missed heart failure.

Based on reviews from: Us2.ai - Healthcare Industry Reviews, Testimonials: What Clinicians & Partners Say | Us2.ai, User Perceptions of AI Echo | Us2.ai, Us2.ai: AI Echocardiography Reporting Software, FDA-Cleared, Advances in AI-Automated Echocardiography with Us2.ai - The Imaging Wire, AI-driven tools into echocardiography practice : r/cardiacsonography - Reddit, Us2.ai Products | Read 0 Reviews on G2, Our Story: The Team Behind AI Echocardiography - Us2.ai, Revolutionizing Tech: Insights from Us2.ai Founder and CEO, eko.ai Pte. Ltd. d/b/a Us2.ai - accessdata.fda.gov

Last updated: 2026-10-20

Videos

News, demos, and interviews about Eko.Ai Pte Ltd. D/B/A Us2.Ai.

Loading videos...

Videos load interactively. If none appear, search YouTube for Eko.Ai Pte Ltd. D/B/A Us2.Ai →

View all on YouTube

Press & Coverage

Us2.ai
Us2.ai receives FDA clearance for Us2.v2, transforming cardiovascular ultrasound analysis
Us2.ai announced FDA clearance for Us2.v2, featuring 45 automated echo parameters including strain analysis, marking a significant advancement in medical innovation for cardiovascular care.
2024-04
Us2.ai
Detection of Cardiac Amyloidosis with Us2.ai: Now FDA cleared and CE marked
Us2.ai's AI Echo Copilot™ software now includes an FDA-cleared and CE-marked feature to assist in the detection of cardiac amyloidosis, authorizing its clinical use globally.
2025-06
Us2.ai
Us2.ai Secures US$15M Series A To Improve AI Detection of Cardiovascular Disease
Us2.ai raised US$15 million in a Series A funding round to expand the clinical implementation of its automated echocardiography report software in the US, Europe, and Asia, and to grow commercial activities with pharmaceutical companies and research labs.
2022-04
StartUp Health
Us2.ai Scores FDA Approval for AI-Driven Heart Exams
This video highlights Us2.ai's FDA approval for its AI software that automates echo exam readings, aiming to democratize access to heart disease diagnostics.
2021-09
Us2.ai
Us2.ai receives FDA clearance for the first fully automated solution measuring both 2D and Doppler cardiac ultrasound images.
Us2.ai announced FDA clearance for its fully automated solution capable of measuring both 2D and Doppler cardiac ultrasound images.
2021-09
Healthcare Industry Reviews
Meet the Innovator: James Hare, CEO of US2.ai
An interview with James Hare, CEO of Us2.ai, discussing the company's mission to tackle cardiovascular disease through pioneering AI and expand healthcare access globally.
2023-11
Deel
How health startup Us2.ai is going global with Deel hassle-free
This article details how Us2.ai utilized Deel's Employer Of Record (EOR) solution to overcome regulatory challenges and efficiently hire remote employees for global expansion.
unknown

Frequently Asked Questions

Us2.ai provides AI-powered automated analysis of echocardiograms, including measurements for heart failure, cardiac amyloidosis, aortic stenosis, pulmonary hypertension, strain imaging, and valvular disease. This automation aims to reduce inter-observer variability, improve efficiency, and provide more consistent and objective cardiac diagnostics compared to manual interpretation.
Us2.ai utilizes deep learning algorithms trained on large datasets to analyze echocardiograms. The company emphasizes its commitment to clinical validation through ongoing clinical trials and research, with published data demonstrating the accuracy and efficiency of its AI models in various cardiac conditions.
Us2.ai offers a suite of products designed for automated echocardiogram analysis, including real-time analysis capabilities and automated reporting. These solutions are built to integrate seamlessly with existing PACS (Picture Archiving and Communication Systems) and can be configured to push data into various EHR systems, streamlining the diagnostic process.
Us2.ai's products have received regulatory clearances in key markets, including FDA 510(k) clearance and CE Mark, indicating their compliance with medical device regulations. The company adheres to strict data privacy and security protocols, including HIPAA and GDPR, to protect patient information.
Us2.ai typically offers flexible pricing models, which may include subscription-based licensing or per-study fees, tailored to the needs of different healthcare institutions. The company provides comprehensive technical support, including onboarding, training for clinical staff, and ongoing assistance to ensure optimal product utilization.
Us2.ai is continuously expanding its AI capabilities to cover a broader range of cardiac conditions and imaging modalities, with a focus on improving diagnostic accuracy and predictive analytics. The company actively collaborates with leading academic institutions, medical device manufacturers, and healthcare providers to advance cardiac care and integrate its technology more widely.
Us2.ai acknowledges the importance of transparency in AI-powered diagnostics. While deep learning models can be complex, Us2.ai's solutions are designed to provide interpretable results and highlight key measurements and findings for physician review. The system acts as a decision-support tool, with the final diagnosis and clinical decision remaining with the physician.

Comparisons

Us2.ca vs EchoNext
Us2.ca vs PMcardio
Us2.ca vs KardiaPro
Atrial Fibrillation History Feature vs Us2.ca

Related Companies

Pe
Perimeter Medical Imaging AI
Toronto, Canada and Dallas, Texas, USA

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]
SOPHiA GENETICS
Rolle, Switzerland and Boston, Massachusetts, United States

SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]
Qure.ai
Mumbai, India

Qure.ai is a leading healthcare AI company that leverages deep learning and artificial intelligence to revolutionize medical imaging diagnostics and make healthcare more accessible and affordable globally. The company develops AI-powered solutions for interpreting X-rays and CT scans, addressing critical health needs in areas such as lung, musculoskeletal, cardiovascular, and neurocritical health. Their technology assists […]
DeepBio
Seoul, South Korea

Deep Bio is a healthcare AI company that develops deep learning-based cancer diagnostic support software, aiming to advance patient outcomes by empowering clinicians with innovative technology. Their mission is to provide tools that enable medical professionals to make critical decisions, ultimately enhancing healthcare delivery and allowing clinicians to focus more on patient care. The company’s […]
CortiCare
Dallas, TX, United States

CortiCare is a healthcare AI company specializing in neuro telemetry and remote patient monitoring, primarily focusing on electroencephalogram (EEG) services. The company provides telehealth services and an EEG brain monitoring platform to neurology and critical care areas within hospitals, including ICUs, NICUs, PICUs, and EMUs. Their services aim to enhance the neurological assessment of adult, […]
CapsoVision
Saratoga, California, United States [1, 2, 11, 13, 17, 19]

CapsoVision is a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (AI) technologies for capsule endoscopy solutions. Their primary goal is to identify abnormalities of the gastrointestinal (GI) tract for diagnostic and screening purposes. [7] Their flagship product, the CapsoCam Plus system, is a single-use capsule endoscope equipped with four cameras, providing […]
Suggest an Edit → | Report an issue
AI Tool Finder
AI-powered search. Results may not be comprehensive.